MarketCap
Facebook
X
Telegram
Viking Therapeutics Balance Sheet 2025-2011 | VKTX
Brief overview of Viking Therapeutics's financial position
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Total assets increased by +239.8%, from $210.7 million to $715.7 million. A CAGR near 35.8% points to substantial expansion.
Funding shifted toward liabilities: they gained +773.4%, compared with +239.8% for assets.
The equity-to-assets ratio is 89.3%, compared with 95.8% five periods ago. The balance sheet has a substantial internal cushion.
The cash share moved from 12.5% to 23.2%. A higher figure generally provides more room in an adverse scenario.
Retained earnings remain negative at -$847.5 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Balance sheet takeaway
The balance sheet gives no single signal for Viking Therapeutics: some indicators are sound, while leverage or capitalization needs attention.
Annual Balance Sheet Viking Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -25.6 M | -54.3 M | -35.1 M | - | -28.8 M | -7.72 M | -24.8 M | -5.54 M | 194 K | 14.7 M | 813 K | 99.1 K | 42.8 K | - |
Long Term Debt |
- | 630 K | 936 K | 1.26 M | - | - | - | - | - | - | 2.15 M | 1.26 M | 232 K | 42.8 K | - |
Long Term Debt Current |
137 K | 489 K | 324 K | 304 K | 29 K | 330 K | 302 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 630 K | 936 K | 1.26 M | - | - | 360 K | 12 K | - | 16.3 K | 4.74 M | 2.65 M | 304 K | 51 K | - |
Total Current Liabilities |
76.7 M | 27.4 M | 19.1 M | 21.9 M | 8.78 M | 12.1 M | 6.78 M | 4.55 M | 8.66 M | 6.48 M | 1.98 M | - | - | - | - |
Total Liabilities |
76.7 M | 28 M | 20.1 M | 23.2 M | 8.78 M | 29 K | 7.14 M | 4.56 M | 8.66 M | 6.49 M | 6.71 M | 25.2 M | 431 K | 105 K | - |
Retained Earnings |
-848 M | -488 M | -378 M | -292 M | -223 M | - | -129 M | -103 M | -80.9 M | -60.3 M | -45.5 M | -22.1 M | -257 K | -111 K | - |
Total Assets |
716 M | 908 M | 368 M | 169 M | 211 M | 257 M | 284 M | 302 M | 22.1 M | 14.5 M | 15.4 M | 3.04 M | 180 K | - | - |
Cash and Cash Equivalents |
166 M | 26.7 M | 55.5 M | 36.6 M | 26.4 M | 29.1 M | 8.38 M | 24.8 M | 8.99 M | 3.08 M | 769 K | 756 K | - | - | - |
Book Value |
639 M | 880 M | 348 M | 145 M | 202 M | 256 M | 277 M | 298 M | 13.5 M | 8.04 M | 8.72 M | -22.1 M | -251 K | -105 K | - |
Total Shareholders Equity |
639 M | 880 M | 348 M | 145 M | 202 M | 244 M | 277 M | 298 M | 13.5 M | 8.04 M | 8.72 M | -22.1 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Viking Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
3.92 M | - | 318 K | 410 K | 502 K | 630 K | 755 K | 766 K | - | 936 K | 1.02 M | 1.1 M | 1.18 M | 1.26 M | 1.34 M | - | 1.49 M | - | - | - | - | 29 K | 29 K | 29 K | 29 K | 360 K | 360 K | 360 K | 360 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
3.92 M | - | 318 K | 410 K | 502 K | 630 K | 755 K | 766 K | - | 936 K | 1.02 M | 1.1 M | 1.18 M | 1.26 M | 1.34 M | - | 1.49 M | - | - | - | - | 29 K | 29 K | 29 K | 29 K | 360 K | 360 K | 360 K | 360 K | 12 K | 12 K | 12 K | 12 K | - | - | 6.05 K | 4.22 M | 16.3 K | 16.3 K | 16.3 K | 16.3 K | 4.74 M | 4.74 M | 4.74 M | 4.74 M | 2.65 M | 2.65 M | 2.65 M | 2.65 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
114 M | 106 M | 26.4 M | 32.4 M | 20.1 M | 28 M | 26.4 M | 25.9 M | - | 20.1 M | 14.4 M | 14.6 M | 16.8 M | 23.2 M | 15.4 M | - | 12.8 M | 8.78 M | 11.4 M | 12.9 M | 12.9 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 7.14 M | 7.14 M | 7.14 M | 7.14 M | 4.56 M | 4.56 M | 4.56 M | 4.56 M | 8.66 M | 8.66 M | 8.66 M | 8.66 M | 6.49 M | 6.49 M | 6.49 M | 6.49 M | 6.71 M | 6.71 M | 6.71 M | 6.71 M | 25.2 M | 25.2 M | 25.2 M | 25.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.13 B | -1.01 B | -690 M | -599 M | -534 M | -488 M | -452 M | -428 M | - | -378 M | -353 M | -331 M | -312 M | -292 M | -272 M | - | -239 M | -223 M | -211 M | -198 M | -182 M | -168 M | -168 M | -168 M | -168 M | -129 M | -129 M | -129 M | -129 M | -103 M | -103 M | -103 M | -103 M | -80.9 M | -80.9 M | -80.9 M | -80.9 M | -60.3 M | -60.3 M | -60.3 M | -60.3 M | -45.5 M | -45.5 M | -45.5 M | -45.5 M | -22.1 M | -22.1 M | -22.1 M | -22.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
522 M | 608 M | 739 M | 828 M | 867 M | 908 M | 938 M | 947 M | - | 368 M | 383 M | 401 M | 151 M | 169 M | 167 M | - | 195 M | 211 M | 224 M | 238 M | 250 M | 257 M | 257 M | 257 M | 257 M | 284 M | 284 M | 284 M | 284 M | 302 M | 302 M | 302 M | 302 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 3.04 M | 3.04 M | 3.04 M | 3.04 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
126 M | 118 M | 100 M | 33.9 M | 37.9 M | 26.7 M | 50.3 M | 43.9 M | - | 55.5 M | 37.2 M | 69.5 M | 18.4 M | 36.6 M | 29.4 M | - | 12.5 M | 26.4 M | 11.3 M | 8.83 M | 16.8 M | 29.1 M | 29.1 M | 29.1 M | 29.1 M | 8.38 M | 8.38 M | 8.38 M | 8.38 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 8.99 M | 8.99 M | 8.99 M | 8.99 M | 3.08 M | 3.08 M | 3.08 M | 3.08 M | 769 K | 769 K | 769 K | 769 K | 756 K | 756 K | 756 K | 756 K | 180 K | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
408 M | 502 M | 713 M | 795 M | 847 M | 880 M | 911 M | 921 M | - | 348 M | 368 M | 386 M | 134 M | 145 M | 151 M | - | 182 M | 202 M | 213 M | 225 M | 237 M | 244 M | 244 M | 244 M | 244 M | 277 M | 277 M | 277 M | 277 M | 298 M | 298 M | 298 M | 298 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 8.04 M | 8.04 M | 8.04 M | 8.04 M | 8.72 M | 8.72 M | 8.72 M | 8.72 M | -22.1 M | -22.1 M | -22.1 M | -22.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
408 M | 502 M | 713 M | 795 M | 847 M | 880 M | 911 M | 921 M | 934 M | 348 M | 368 M | 386 M | 134 M | 145 M | 151 M | 165 M | 182 M | 202 M | 213 M | 225 M | 237 M | 244 M | 244 M | 244 M | 244 M | 277 M | 277 M | 277 M | 277 M | 298 M | 298 M | 298 M | 298 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 8.04 M | 8.04 M | 8.04 M | 8.04 M | 8.72 M | 8.72 M | 8.72 M | 8.72 M | -22.1 M | -22.1 M | -22.1 M | -22.1 M | -251 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Viking Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
